559
Participants
Start Date
April 10, 2024
Primary Completion Date
January 31, 2032
Study Completion Date
July 31, 2032
Daratumumab
Dose determined at enrollment
Lenalidomide
Dose determined at enrollment
Dexamethasone
Dose determined at enrollment
RECRUITING
BCCA - Kelowna, Kelowna
RECRUITING
BCCA - Vancouver, Vancouver
RECRUITING
CancerCare Manitoba, Winnipeg
RECRUITING
The Moncton Hospital, Moncton
RECRUITING
Regional Health Authority B, Zone 2, Saint John
RECRUITING
Dr. H. Bliss Murphy Cancer Centre, St. John's
RECRUITING
Royal Victoria Regional Health Centre, Barrie
RECRUITING
William Osler Health System, Brampton
RECRUITING
Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton
RECRUITING
Kingston Health Sciences Centre, Kingston
RECRUITING
Waterloo Regional Health Network (WRHN), Kitchener
RECRUITING
London Health Sciences Centre Research Inc., London
RECRUITING
Stronach Regional Health Centre at Southlake, Newmarket
RECRUITING
Lakeridge Health Oshawa, Oshawa
RECRUITING
Ottawa Hospital Research Institute, Ottawa
RECRUITING
Algoma District Cancer Program, Sault Ste. Marie
RECRUITING
Niagara Health System, St. Catharines
RECRUITING
St. Michael's Hospital, Toronto
RECRUITING
St. Joseph's Health Centre, Toronto
RECRUITING
Windsor Regional Cancer Centre, Windsor
RECRUITING
CIUSSS de l'Est-de-I'lle-de-Montreal, Montreal
RECRUITING
The Jewish General Hospital, Montreal
NOT_YET_RECRUITING
The Research Institute of the McGill University, Montreal
RECRUITING
CHU de Quebec-Hopital l'Enfant-Jesus (HEJ), Québec
RECRUITING
Allan Blair Cancer Centre, Regina
RECRUITING
Saskatoon Cancer Centre, Saskatoon
Canadian Institutes of Health Research (CIHR)
OTHER_GOV
Myeloma Canada
UNKNOWN
Canadian Cancer Trials Group
NETWORK